Picture loading failed.

Pre-Made Galiximab biosimilar, Whole mAb, Anti-CD80 Antibody: Anti-B7/BB1/B7-1/B7.1/LAB7/CD28LG/CD28LG1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Galiximab is a monoclonal antibody designed for the treatment of B-cell lymphoma. As of September 2009, it is undergoing Phase III clinical trials. The drug is a chimeric antibody from Macaca irus and Homo sapiens.

Order information


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-229-1mg 1mg 3090
GMP-Bios-ab-229-10mg 10mg 21890
GMP-Bios-ab-229-100mg 100mg 148000
GMP-Bios-ab-229-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Galiximab biosimilar, Whole mAb, Anti-CD80 Antibody: Anti-B7/BB1/B7-1/B7.1/LAB7/CD28LG/CD28LG1 therapeutic antibody
INN Name Galiximab
TargetCD80
FormatWhole mAb
DerivationChimeric (Mouse/Human)
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCLambda
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2003
Year Recommended2004
CompaniesBiogen;Biogen Idec
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedAutoimmune disorders;Non-Hodgkin's lymphoma;Psoriasis
Development Techna